Aisen PS - Search Results

1

Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model.

Hirata-Fukae C, Li HF, Hoe HS, Gray AJ, Minami SS, Hamada K, Niikura T, Hua F, Tsukagoshi-Nagai H, Horikoshi-Sakuraba Y, Mughal M, Rebeck GW, LaFerla FM, Mattson MP, Iwata N, Saido TC, Klein WL, Duff KE, Aisen PS, Matsuoka Y. Hirata-Fukae C, et al. Among authors: aisen ps. Brain Res. 2008 Jun 24;1216:92-103. doi: 10.1016/j.brainres.2008.03.079. Epub 2008 Apr 10. Brain Res. 2008. PMID: 18486110

2

The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease.

Aisen PS. Aisen PS. Lancet Neurol. 2002 Sep;1(5):279-84. doi: 10.1016/s1474-4422(02)00133-3. Lancet Neurol. 2002. PMID: 12849425 Review.

3

Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant.

Horikoshi Y, Sakaguchi G, Becker AG, Gray AJ, Duff K, Aisen PS, Yamaguchi H, Maeda M, Kinoshita N, Matsuoka Y. Horikoshi Y, et al. Among authors: aisen ps. Biochem Biophys Res Commun. 2004 Jul 2;319(3):733-7. doi: 10.1016/j.bbrc.2004.05.051. Biochem Biophys Res Commun. 2004. PMID: 15184044

4

An Abeta sequestration approach using non-antibody Abeta binding agents.

Matsuoka Y, Shao L, Debnath M, Lafrancois J, Becker A, Gray A, Aisen P, Mathis C, Klunk W, Duff K. Matsuoka Y, et al. Curr Alzheimer Res. 2005 Apr;2(2):265-8. doi: 10.2174/1567205053585774. Curr Alzheimer Res. 2005. PMID: 15974928

5

The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors.

Aisen PS. Aisen PS. CNS Drugs. 2005;19(12):989-96. doi: 10.2165/00023210-200519120-00002. CNS Drugs. 2005. PMID: 16332141 Review.

6

In vivo protein transduction to the CNS.

Loftus LT, Li HF, Gray AJ, Hirata-Fukae C, Stoica BA, Futami J, Yamada H, Aisen PS, Matsuoka Y. Loftus LT, et al. Among authors: aisen ps. Neuroscience. 2006;139(3):1061-7. doi: 10.1016/j.neuroscience.2006.01.041. Epub 2006 Mar 9. Neuroscience. 2006. PMID: 16529872

7

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.

Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, Garceau D. Aisen PS, et al. Neurology. 2006 Nov 28;67(10):1757-63. doi: 10.1212/01.wnl.0000244346.08950.64. Epub 2006 Nov 2. Neurology. 2006. PMID: 17082468 Clinical Trial.

8

BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.

Nishitomi K, Sakaguchi G, Horikoshi Y, Gray AJ, Maeda M, Hirata-Fukae C, Becker AG, Hosono M, Sakaguchi I, Minami SS, Nakajima Y, Li HF, Takeyama C, Kihara T, Ota A, Wong PC, Aisen PS, Kato A, Kinoshita N, Matsuoka Y. Nishitomi K, et al. Among authors: aisen ps. J Neurochem. 2006 Dec;99(6):1555-63. doi: 10.1111/j.1471-4159.2006.04178.x. Epub 2006 Nov 2. J Neurochem. 2006. PMID: 17083447 Free article.

9

Antibody against C-terminal Abeta selectively elevates plasma Abeta.

Gray AJ, Sakaguchi G, Shiratori C, Becker AG, LaFrancois J, Aisen PS, Duff K, Matsuoka Y. Gray AJ, et al. Among authors: aisen ps. Neuroreport. 2007 Feb 12;18(3):293-6. doi: 10.1097/WNR.0b013e3280148e76. Neuroreport. 2007. PMID: 17314674

10

Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage.

Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, LaFerla FM, Gozes I, Aisen PS. Matsuoka Y, et al. Among authors: aisen ps. J Mol Neurosci. 2007;31(2):165-70. doi: 10.1385/jmn/31:02:165. J Mol Neurosci. 2007. PMID: 17478890

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

627 results

Search Page

Filters